|
2019 Conference Publication Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. L. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, A. C., Geiger, J., Stankevich, E., Li, S., Lowy, I., Fury, M. G. and Guminski, A. (2019). Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Conference Publication Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 studyGrob, J. J., Gonzalez Mendoza, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J., Zhang, P., Gumuscu, B., Swaby, R. F. and Hughes, B. G. M. (2019). Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona Spain, Sep 27-Oct 01, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Conference Publication KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinomaGrob, Jean-Jacques, Gonzalez Mendoza, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica, Grange, Florent, Meyer, Nicolas, Piulats, Josep, Zhang, Pingye (Eric), Gumuscu, Burak, Swaby, Ramona and Hughes, Brett G. M. (2019). KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-CT170 |
|
2019 Conference Publication Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129 |
|
2019 Conference Publication KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)Grob, Jean Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica Ruth, Grange, Florent, Meyer, Nicolas, Piulats, Josep M., Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett Gordon Maxwell (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.TPS9598 |
|
2019 Conference Publication Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC)Wirth, Lori J., Leboulleux, Sophie, Kiyota, Naomi, Tahara, Makoto, Muro, Kei, Ahn, Myung-Ju, Ando, Yuichi, Taylor, Matthew H., Takahashi, Shunji, Kim, Sung-Bae, Misir, Soamnauth, Dutcus, Corina E., Xie, Ran, Joshi, Prashant Ramesh, Hughes, Brett Gordon Maxwell, Aller, Javier, Krzyzanowska, Monika K. and Capdevila, Jaume (2019). Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6081 |
|
2019 Conference Publication Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET stagingSenko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. |
|
2019 Conference Publication Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Baste, Neus, Neupane, Prakash C., Bratland, Ase, Fuereder, Thorsten, Hughes, Brett Gordon Maxwell, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Zhang, Yayan, Jin, Fan, Gumuscu, Burak and Burtness, Barbara (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6000 |
|
2019 Conference Publication Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-upGuminski, Alexander David, Lim, Annette May Ling, Khushalani, Nikhil I., Schmults, Chrysalyne D., Hernandez-Aya, Leonel Fernando, Modi, Badri, Dunn, Lara, Hughes, Brett Gordon Maxwell, Chang, Anne Lynn S., Hauschild, Axel, Migden, Michael Robert, Gutzmer, Ralf, Alam, Murad, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.9526 |
|
2018 Conference Publication Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P. C., Bratland,, Fuereder, T., Hughes, B. G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.045 |
|
2018 Conference Publication Thromboembolism in ROS1 Rearranged Non-Small Cell Lung CancerItchins, M., Alexander, M., John, T., Kao, S., Hughes, B., Hayes, S., Howel, V., Harvie, R., Clarke, S., Millward, M. and Pavlakis, N. (2018). Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jtho.2018.08.1104 |
|
2018 Conference Publication KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., De Castro, G., Psyrri, A., Rotllan, N. Baste, Neupane, P. C., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. Wan, Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancerRatnayake, G., Shankar, M., Roberts, K., Mason, R., Hughes, B. G. M., Lwin, Z., Jain, V., O'Byrne, K. J. and Chua, B. (2018). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. 43rd ESMO Congress (ESMO), Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy292.093 |
|
2018 Conference Publication BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLCKulkarni, S., Laurie, S., Goss, G., Perrone, F., Hughes, B., Pavlakis, N., Stockler, M., Blais, A., Zibdawi, L., Vera-Badillo, F. and Leighl, N. (2018). BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC. IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 23-26 September 2018. New York, NY USA: Elsevier. doi: 10.1016/j.jtho.2018.08.608 |
|
2018 Conference Publication Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLCSocinski, M. A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R. A., Palmero, R., Kozuki, T., Migliorino, M. R., Koynov, K. D., Berard, H., Hughes, B. G. M., Yu, W., Graupner, V., Sun, S. W., Kowanetz, M., Hoang, T., Lin, W. and Jotte, R. M. (2018). Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC. 43rd ESMO Congress, Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy424.077 |
|
2017 Conference Publication Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology CentersRoberts, K., Mason, R., Hughes, B., Lwin, Z., Jain, V. and O'Byrne, K. (2017). Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centers. HOBOKEN: WILEY. |
|
2017 Conference Publication Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)Mauti, L., Rivalland, G., Klingbiel, D., Kao, S., Schmid, S., Nowak, A., Gautschi, O., Hughes, B., Bartnick, T., Pavlakis, N., Bouchaab, H., O'Byrne, K., Rothschild, S., Russell, P., Savic Prince, S., Thapa, B., Pless, M., von Moos, R., Metaxas, Y. and John, T. (2017). Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH). ESMO Immuno Oncology Congress 2017, Geneva, Switzerland, 7–10 December 2017. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdx711.007 |
|
2016 Conference Publication The Significance of Pulmonary Nodules in Head and Neck CancerLadwa, R., Xu, W., Tani, D., Wockener, L., Williamson, K., Lwin, Z., Ritchie, A., Steinke, K. and Hughes, B. (2016). The Significance of Pulmonary Nodules in Head and Neck Cancer. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Lean Thinking: Exploring Overhead and Supplementary Tasks (Ost) in Cancer Care (Cc) in the Oncology Outpatient Encounter (Ooe)Peters, G., Smith, D., Rasool, M., Ladwa, R., Hughes, B. and Lwin, Z. (2016). Lean Thinking: Exploring Overhead and Supplementary Tasks (Ost) in Cancer Care (Cc) in the Oncology Outpatient Encounter (Ooe). HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Pneumocystis pneumonia (Pjp) in lung cancer patientsChavalertsakul, Nuttaya, Lwin, Zarnie, Hay, Karen and Hughes, Brett (2016). Pneumocystis pneumonia (Pjp) in lung cancer patients. COSA's 43rd and ANZBCTG's 38th Annual Scientific Meetings. Partners for Progress in Breast Cancer Research and Care, Gold Coast, QLD Australia, 15-17 November 2016. HOBOKEN: WILEY-BLACKWELL. |
